IQVIA (IQV)
(Delayed Data from NYSE)
$251.55 USD
+0.76 (0.30%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $251.48 -0.07 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$251.55 USD
+0.76 (0.30%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $251.48 -0.07 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Thermo Fisher (TMO) Up 1.6% Since Last Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IQVIA (IQV) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain IQVIA (IQV) Stock for Now
by Zacks Equity Research
IQVIA (IQV) rides high on robust segmental performance, boosting the company's top line. However, elevated operating expenses and weak liquidity are a major concern.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Waste Connections (WCN) Marginally Dips Despite Q2 Earnings Beat
by Zacks Equity Research
Waste Connections (WCN) records improved segmental performances in the second quarter of 2024.
S&P Global (SPGI) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
S&P Global's (SPGI) second-quarter 2024 earnings and revenues increase year over year.
Understanding IQVIA (IQV) Reliance on International Revenue
by Zacks Equity Research
Examine the evolution of IQVIA's (IQV) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Waste Management (WM) Q2 Earnings Meet Estimates, Rise Y/Y
by Zacks Equity Research
Waste Management's (WM) second-quarter 2024 earnings and revenues rise year over year.
Top Analyst Reports for SAP, Abbott Laboratories & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Abbott Laboratories (ABT) and Citigroup Inc. (C), as well as two micro-cap stocks Team, Inc. (TISI) and Vaso Corporation (VASO).
Fiserv (FI) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Fiserv's (FI) second-quarter 2024 revenues and earnings increase year over year.
IQV vs. WAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
IQV vs. WAT: Which Stock Is the Better Value Option?
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Stock Market News for Jul 23, 2024
by Zacks Equity Research
U.S. stock markets closed higher on Monday after a disappointing last week.
Compared to Estimates, IQVIA (IQV) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for IQVIA (IQV) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IQVIA (IQV) Surpasses Earnings & Revenue Estimates in Q2
by Zacks Equity Research
IQVIA's (IQV) second-quarter 2024 earnings and revenues increase year over year.
Clarivate (CLVT) to Develop Unified Library Solution for Ohio
by Subham Roy
Clarivate (CLVT) partners with OhioLINK and SearchOhio to integrate their INN-Reach platforms to develop a unified library solution for the state of Ohio.
IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 2.33% and 0.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
IQVIA's (IQV) second-quarter 2024 revenues are likely to have gained from growth in the Technology and Analytics, and Research and Development segments.
Clinical Development Expertise Aids IQVIA (IQV), Costs High
by Zacks Equity Research
IQVIA (IQV) benefits from its healthcare-specific global IT infrastructure and domain expertise to expand and penetrate different markets.
Paychex (PAYX) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Paychex's (PAYX) fourth-quarter fiscal 2024 earnings and revenues are expected to have increased year over year.